Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.
William D Tap, Gregory M Cote, Howard Burris...
https://pubmed.ncbi.nlm.nih.gov/40100120/Actively Recruiting
Led by Servier Bio-Innovation LLC · Updated on 2026-10-28
156
Participants Needed
115
Research Sites
147 weeks
Total Duration
Researchers are evaluating the use of oral ivosidenib in adults with locally advanced or metastatic conventional chondrosarcoma that has an IDH1 gene mutation. This Phase 3, international, multicenter, double-blind study compares ivosidenib to a placebo in participants who have measurable disease that has progressed or recurred and who have received up to two prior systemic treatments. The trial focuses on progression-free survival as the primary outcome, especially in Grades 1 and 2 chondrosarcoma participants. Participants will be randomly assigned to receive either ivosidenib 500 mg tablets or matching placebo tablets taken orally once daily. Treatment continues until disease progression confirmed by a blinded independent central review, unacceptable side effects, pregnancy, death, withdrawal, loss to follow-up, or study end. Those on placebo who experience disease progression and meet criteria may cross over to receive ivosidenib. The estimated average treatment duration is about two years. During the study, participants will undergo regular imaging scans to assess tumor response and progression according to RECIST criteria. Researchers will monitor survival outcomes up to five years and evaluate safety through adverse event reporting. Quality of life questionnaires and blood tests to measure drug and biomarker levels will be collected. The total participation duration may extend up to five years, including treatment and follow-up assessments.
CONDITIONS
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
I
Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Servier Bio-Innovation LLC
Lead Sponsor
Institut de Recherches Internationales Servier
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Ivosidenib | Placebo |
|---|---|---|
| What the option is | An investigational oral tablet that specifically inhibits mutant IDH1 enzyme | An oral placebo tablet given once daily matching the investigational arm |
| Role in trial | Experimental targeted therapy under investigation | Control comparator to enable randomized evaluation |
| Purpose in trial | To evaluate impact on progression‑free survival in IDH1‑mutated chondrosarcoma | To serve as the blinded comparator for assessing progression‑free survival |
| How it is given | Taken orally as tablets once daily (500 mg total dose) | Taken orally as placebo tablets once daily matching active dosing |
| Broader clinical evidence | Early phase I data show manageable safety and durable disease control in IDH1‑mutated chondrosarcoma | Placebos provide no therapeutic benefit by design |
| Important risks | Manageable toxicity observed in early studies; some serious adverse events occurred but none were attributed to the drug | No drug‑related risks since placebo is inactive |
| Key limitations | Evidence is limited to early‑phase data; efficacy compared only against placebo, not active therapy | No clinical activity expected; serves only as control arm |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - Up to 4 weeks
Participants are screened to confirm eligibility, including diagnosis, mutation status, prior treatments, and disease progression.
1 to 2 visits
Duration - Up to approximately 2 years
Participants receive oral ivosidenib 500 mg or matching placebo daily. Treatment continues until disease progression, unacceptable side effects, or other specified reasons.
Regular visits for monitoring and assessments
Duration - Up to 5 years
Participants are monitored for survival and long-term outcomes, with assessments including imaging and safety evaluations.
Periodic visits for survival and safety assessments
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
William D Tap, Gregory M Cote, Howard Burris...
https://pubmed.ncbi.nlm.nih.gov/40100120/Servier Bio-Innovation LLC
Lead Sponsor
Institut de Recherches Internationales Servier
Collaborating Sponsor